Anthem Biosciences IPO

Integrated CRDMO Services Across the Drug Lifecycle: Anthem Biosciences offers comprehensive services from drug discovery to commercial manufacturing covering small molecules and biologics. This end-to-end model positions the company as a one-stop solution in the growing CRDMO sector.

Strong Focus on Innovation and Advanced Technology: With an innovation-led approach, Anthem leverages cutting-edge technologies to handle complex manufacturing projects, including biosimilars, enzymes, and peptides ensuring long-term relevance and scalability.

Unique Business Model for Small Pharma and Biotech Clients: The company’s differentiated model caters to the specific needs of emerging biotech startups and smaller pharmaceutical firms helping them scale from discovery to market-ready products.

Scalable and Automated Infrastructure: Anthem’s fully developed manufacturing infrastructure is highly automated and built to scale allowing efficiency in production and a faster turnaround across global customer requirements.

High Revenue Dependency on CRDMO Segment: In FY25, 81.65% of total revenue came from CRDMO services. Such high concentration in a single business vertical increases the risk if market dynamics shift.

Exposure to Early-Stage Project Failures: A significant portion of the company’s pipeline includes early-phase development projects. Any failures or delays at this stage could directly impact earnings and resource utilization.

Continuous Investment Required in Technology: The pharmaceutical R&D space evolves rapidly. Anthem needs to constantly upgrade its technology to remain competitive, which could put pressure on capital expenditure and margins.

Client Concentration Risk: The company relies heavily on a few clients with the top 5 contributing 70.92% and the top 10 contributing 77.33% of FY25 revenue. Any loss or shift in key clients could significantly affect financial stability.